Ibere Pharmaceuticals (IBER) Short Interest Ratio & Short Volume

Short interest is the volume of Ibere Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of February 15th, traders have sold 15,600 shares of IBER short. 0.11% of Ibere Pharmaceuticals' shares are currently sold short. Learn More on Ibere Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.11% of Ibere Pharmaceuticals' floating shares are currently sold short.

Ibere Pharmaceuticals saw a decline in short interest in February. As of February 15th, there was short interest totaling 15,600 shares, a decline of 24.3% from the previous total of 20,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Ibere Pharmaceuticals currently has issued a total of 17,250,000 shares. Some of Ibere Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ibere Pharmaceuticals currently has a public float of 13,800,000 shares.

0.11% of Ibere Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Ibere Pharmaceuticals: ARYA Sciences Acquisition Corp IV (0.00%), Future Health ESG Corp. (0.16%), enGene Holdings Inc. (0.17%), Vaxart, Inc. (9.89%), Orchestra BioMed Holdings, Inc. (4.07%), scPharmaceuticals Inc. (19.70%), Regulus Therapeutics Inc. (9.44%), Adicet Bio, Inc. (9.36%), Amylyx Pharmaceuticals, Inc. (12.63%), Lifecore Biomedical, Inc. (6.04%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.09 billion), Occidental Petroleum Co. ($3.00 billion), T. Rowe Price Group, Inc. ($2.35 billion), Coinbase Global, Inc. ($2.30 billion), Paramount Global ($2.04 billion), Etsy, Inc. ($1.90 billion), Voya Financial, Inc. ($1.77 billion), CarMax, Inc. ($1.67 billion), Royal Caribbean Cruises Ltd. ($1.58 billion), and Monolithic Power Systems, Inc. ($1.47 billion). View all of the most shorted stocks.

Short selling IBER is an investing strategy that aims to generate trading profit from Ibere Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Ibere Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IBER, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IBER, twice per month. The most recent reporting period available is February, 15 2023.